Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & Administrative
Others
Ratios

Molecular Partners Ag (MOLN) EBITDA (2021 - 2025)

Historic EBITDA for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to -$15.1 billion.

  • Molecular Partners Ag's EBITDA fell 8941961746.93% to -$15.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.1 billion, marking a year-over-year decrease of 8520470.29%. This contributed to the annual value of -$69.57 for FY2024, which is 20099.41% down from last year.
  • Molecular Partners Ag's EBITDA amounted to -$15.1 billion in Q3 2025, which was down 8941961746.93% from -$20.92 recorded in Q2 2025.
  • Molecular Partners Ag's 5-year EBITDA high stood at $165.2 billion for Q1 2022, and its period low was -$20.5 billion during Q1 2021.
  • Over the past 5 years, Molecular Partners Ag's median EBITDA value was -$16312.6 (recorded in 2023), while the average stood at $9.9 billion.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 90597.5% in 2022, then tumbled by 8941961746.93% in 2025.
  • Quarter analysis of 5 years shows Molecular Partners Ag's EBITDA stood at $51.7 billion in 2021, then plummeted by 99.77% to $120.9 million in 2022, then crashed by 99.96% to $50191.1 in 2023, then rose by 5.44% to $52923.0 in 2024, then tumbled by 28451138.84% to -$15.1 billion in 2025.
  • Its last three reported values are -$15.1 billion in Q3 2025, -$20.92 for Q2 2025, and -$17953.9 during Q1 2025.